Figures

0.2.1 How does money flow through the health system? The health financing functions *page* 2
0.2.2 Average share of health spending by financing agent, by country income grouping, 2021 8
1.1.1 Public financing is a much bigger share of health spending in richer countries 40
1.1.2 OOP falls as public spending grows: the inverse relationship between public versus OOP spending on health, 2019 41
1.1.3 Spending has increased across the board but patterns of spending have evolved differently in low-, middle- and high-income countries 42
1.1.4 General government revenues are a small proportion of GDP in lower-income countries 45
1.1.5 Old-age dependency ratios are projected to increase in many (middle- to higher-income) countries 54
1.3.1 In 2021, the number of countries in which VHI accounted for at least 10% of current spending on health was very small 97
1.3.2 In 2021, the VHI share of current spending on health was highest in UMICs 97
1.3.3 In 2021 the VHI share of current spending on health was higher in the Americas than in other parts of the world 98
1.3.4 Not many countries saw substantial changes in the VHI share of current spending on health between 2000 and 2021 99
1.3.5 Public spending on health is more likely to reduce OOPs than VHI 104
2.1.1 Pooling arrangement classifications 144

Published online by Cambridge University Press

2.2.1 A benefits package involves consideration of coverage in terms of cost, service and population 167
2.2.2 A framework can be used to help identify "best buys" and priorities for the health system given different budget thresholds 185
2.2.3 A generic framework for setting a benefits package will require context-specific interpretation 189
2.3.1 Conceptual framework for disinvestment from low-value care 198
2.4.1 OOP spending disproportionately finances pharmacies as compared to hospitals 228
2.4.2 Households in the poorest quintile have the highest level of catastrophic spending due to OOP payments 232
2.4.3 OOP spending can push households below or further below the poverty line 233
2.4.4 Low-income individuals are particularly vulnerable to experiencing unmet needs for health care due to cost 235
2.5.1 On average, OECD countries have five formal LTC workers per 100 people aged 65 years and over 249
2.5.2 Across 18 OECD countries, more than 1 in 10 people aged 50 years and older report providing informal care at least weekly 251
2.5.3 Women are most likely to take on the role of informal carer 251
2.5.4 A majority of OECD countries are moving LTC from residential facilities into the community 253
2.5.6 The largest share of total LTC spending in OECD countries is on nursing homes 261
2.5.7 Without public social protection, the majority of older individuals would not be able to afford LTC from their incomes alone 263
2.5.8 Instruments and procedures used to assess LTC needs vary widely 266
2.5.9 Nearly a third of people 65 years and older in the EU report at least one ADL/IADL limitation 271
2.5.10 The majority of LTC users are women and those aged 80 years and above 273

Published online by Cambridge University Press

2.5.11	Just over half of older people reporting a need for help also report receiving help for it	274
3.2.1	Schema of payment flows in England	347
3.3.1	Prevalence of informal payments in selected countries, 2019–2021	385
3.3.2	Prevalence of informal payments in the EU, 2021	385
3.3.3	Prevalence of informal payments in the Asia–Pacific region, 2020	387
3.3.4	Share of GDP spent on health care versus percentage of patients who paid informally in the past 12 months, 2019–2021	388
3.3.5	OOP payments as share of total health spending versus percentage of patients who have paid informally in the past 12 months, 2019–2021	389
3.3.6	Physician density versus percentage of patients who have paid informally in the past 12 months, 2014–2021	390
3.4.1	Pharmaceutical expenditures are composed of the volume of medicines consumed times their prices	426
3.5.1	Three bundled payment schemes and how they vary on key dimensions	462
3.6.1	Framework to analyse financial flows in LTC and payments for providers	481
3.9.1	Number of new classes of antibiotics discovered or patented each decade	575
3.9.2	Antibiotic value chain and the barriers to R&D progression	577
3.9.3	Framework for developing a holistic incentive package for antibiotic development	581
3.9.4	Antibiotic drugs and alternative antibacterial therapies in clinical development	593
3.9.5	Types of alternative antibacterial therapies in development	595
3.9.6	Continuum of incentivization across the antibiotic value chain	596
3.10.1	Neglected diseases disproportionately affect LMICs	613
3.10.2	Neglected diseases have declined in richer countries but remain constant in LMICs	614

Published online by Cambridge University Press

3.10.3	Top five neglected diseases: diarrhoeal diseases, HIV/AIDS, malaria, TB, and typhoid and paratyphoid	614
3.10.4	Global pharmaceutical companies are underinvesting in neglected disease R&D, 2019	617
3.10.5	Most money is spent on vaccines, drugs and basic research	617
3.10.6	Most R&D spending to address neglected disease challenges goes on just two stages	618
3.10.7	Academics and research institutions receive the biggest proportion of investment	619
3.10.8	Low-burden diseases receive more than their fair share of R&D	620
3.10.9	LMICs receive few market launches for new pharmaceutical products	621
3.10.10	HIV/AIDS, malaria and TB receive most investment	622
3.10.11 and 12	Low-burden diseases received more than their fair share of funding	623

Published online by Cambridge University Press